Kangji Medical Holdings Limited (9997) AI Stock Analysis

• Market Cap: HK$9.19B
• Dividend Yield: 15.41%
• Average Volume (3M): 2.65M
• Price to Earnings (P/E): 14.0
• Beta (1Y): 0.70
• Revenue Growth: 7.13%
• EPS Growth: 13.39%
• Country: HK
• Employees: 1,007
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 0.54
• Shares Outstanding: 1,207,994,000
• 10 Day Avg. Volume: 2,168,942
• 30 Day Avg. Volume: 2,645,601
• PEG Ratio: 1.54
• Price to Book (P/B): 3.03
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 15.78
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

Kangji Medical Holdings Limited shows strong financial performance with consistent revenue growth, high profitability, and robust cash generation, which significantly supports its overall stock score. The positive technical analysis trend is a secondary strength. The valuation is balanced by a moderate P/E ratio and an attractive dividend yield, adding to the stock's appeal. The absence of earnings call and corporate events information did not impact the score.

Kangji Medical Holdings Limited Business Overview & Revenue Model

Company Description

Kangji Medical Holdings Limited (9997) is a leading Chinese medical device company specializing in the development, manufacturing, and marketing of minimally invasive surgical instruments and accessories. The company's product portfolio includes disposable and reusable surgical instruments that cater to various medical specialties, including gynecology, urology, and general surgery. Kangji Medical is committed to enhancing surgical outcomes and patient care through innovative and high-quality medical solutions.

How the Company Makes Money

Kangji Medical Holdings Limited generates revenue primarily through the sale of its minimally invasive surgical instruments and accessories. The company's revenue streams are largely driven by the demand for its disposable and reusable products used in surgical procedures across hospitals and healthcare facilities. Kangji Medical also benefits from strategic partnerships with medical institutions and continued investment in research and development to expand its product offerings. The company's growth is further supported by the increasing adoption of minimally invasive surgical techniques in China and other markets.

Kangji Medical Holdings Limited Financial Statement Overview

Summary

Kangji Medical Holdings Limited exhibits strong financial performance across all verticals. The income statement reveals consistent revenue and profitability growth, while the balance sheet shows financial stability with low leverage. The cash flow statement indicates robust cash generation and efficient capital management. Overall, the company is well-positioned for future growth with its solid financial foundation.

Income Statement

Kangji Medical Holdings Limited has demonstrated consistent revenue growth over the years, with a significant increase in total revenue from 2023 to 2024. The company maintains high gross profit margins, indicating strong cost control and pricing power. The net profit margin is also robust, reflecting efficient operations and profitability. EBIT and EBITDA margins are healthy, showcasing strong operational performance.

Balance Sheet

The balance sheet is strong, with a low debt-to-equity ratio due to minimal total debt, indicating low financial risk. The company has a high equity ratio, signifying a substantial equity base relative to total assets. Return on equity is impressive, suggesting effective use of shareholders' funds to generate profits. Overall, the balance sheet reflects financial stability and conservative leverage.

Cash Flow

The cash flow statement shows substantial operating cash flow, comfortably covering net income, highlighting strong cash generation. Free cash flow has grown significantly, pointing to effective capital expenditure management. The company's ability to maintain positive free cash flow alongside growth indicates a solid cash position and investment capacity.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.01B	926.02M	786.37M	690.26M	511.49M
	Gross Profit
797.65M	741.20M	635.25M	562.93M	431.47M
	EBIT
592.69M	442.47M	446.02M	417.74M	311.67M
	EBITDA
562.61M	464.58M	586.65M	427.25M	319.14M
	Net Income Common Stockholders
581.44M	504.02M	478.74M	456.79M	250.30M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.24B	2.69B	2.83B	3.01B	2.78B
	Total Assets
2.92B	4.26B	3.98B	3.39B	3.02B
	Total Debt
3.52M	43.99M	49.02M	4.05M	5.05M
	Net Debt
-1.12B	-2.63B	-2.77B	-2.95B	-2.23B
	Total Liabilities
289.39M	319.97M	266.10M	129.94M	83.65M
	Stockholders Equity
2.63B	3.65B	3.37B	3.26B	2.94B
Cash Flow		Free Cash Flow
504.52M	331.70M	243.62M	404.88M	203.21M
	Operating Cash Flow
560.10M	419.62M	319.31M	435.75M	221.04M
	Investing Cash Flow
1.04B	-391.70M	-369.98M	-160.09M	-610.98M
	Financing Cash Flow
-1.70B	-243.53M	-472.79M	-97.61M	2.15B

Kangji Medical Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.53
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:9997, the sentiment is Positive. The current price of 7.53 is above the 20-day moving average (MA) of 7.31, above the 50-day MA of 7.37, and above the 200-day MA of 6.33, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 55.97 is Neutral, neither overbought nor oversold. The STOCH value of 47.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:9997.

Kangji Medical Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
9997	81 Outperform	HK$9.19B	14.04	18.36%	15.41%	7.13%	13.39%
2269	78 Outperform	$95.66B	26.56	8.17%	―	7.52%	-1.92%
6826	68 Neutral	HK$11.66B	12.23	7.25%	5.24%	-1.81%	-3.79%
6080	67 Neutral	HK$92.44M	15.00	4.66%	―	58.64%	106.25%
2196	65 Neutral	$62.64B	12.54	6.22%	1.97%	-2.82%	11.93%
6886	64 Neutral	$155.18B	7.23	9.25%	3.42%	-25.29%	17.94%
Sector *	52 Neutral	$5.15B	3.05	-44.13%	2.84%	16.42%	-0.48%

Kangji Medical Holdings Limited Corporate Events

Kangji Medical Terminates Subsidiary Disposal, Secures Land Resumption Deal

Kangji Medical Holdings Limited announced the termination of a discloseable transaction involving the disposal of a subsidiary due to the purchaser’s inability to fulfill payment obligations. The termination agreement allows Kangji to retain RMB46 million and includes provisions for the return of company records and land resumption. Additionally, Kangji entered a land resumption agreement with a PRC government authority, resulting in a compensation of approximately RMB29.3 million. The company expects to realize a gain of RMB39.3 million from these agreements, impacting its financial position positively.

Kangji Medical Holdings Schedules 2025 Annual General Meeting

Kangji Medical Holdings Limited has announced its upcoming annual general meeting scheduled for May 23, 2025, in Hong Kong. Key agenda items include the approval of audited financial statements for 2024, a final dividend declaration of RMB24 cents per share, re-election of independent non-executive directors, and re-appointment of Ernst & Young as auditors. The meeting will also address resolutions concerning the issuance and management of company shares, indicating a strategic focus on financial stability and governance.

Kangji Medical’s Associate Gains Approval for Innovative Surgical Robot

Kangji Medical Holdings Limited announced that its associate, Hangzhou Weijing Medical Robot Co., Ltd., has received regulatory approval from China’s National Medical Products Administration for its four-arm laparoscopic surgical robot. This approval marks a significant milestone in Weijing Medical’s commercialization efforts and strengthens Kangji Medical’s strategic position in the minimally invasive surgery market. The company plans to leverage its sales, distribution, and manufacturing capabilities to support the development and commercialization of Weijing Medical’s surgical robotic systems.